Aberrant expression of HOX and MEIS1 family genes, as seen in KMT2A-rearranged,
NUP98-rearranged, or NPM1-mutated leukemias leads to arrested differentiation and …

The AML treatment landscape has significantly changed in recent years with the approval of
targeted therapies in the front-line and relapsed/refractory settings, including inhibitors of …

KMT2A (alias: mixed-lineage leukemia [MLL]) gene mapping on chromosome 11q23
encodes the lysine-specific histone N-methyltransferase 2A and promotes transcription by …

Acute myeloid leukemia (AML) is a common hematologic malignancy that is considered to
be a disease of aging, and traditionally has been treated with induction chemotherapy …

The protein menin is encoded by the MEN1 gene and primarily serves as a nuclear scaffold
protein, regulating gene expression through its interaction with and regulation of chromatin …

Introduction The treatment of multiple myeloma (MM) is evolving rapidly. Quadruplet
regimens incorporating proteasome inhibitors, immunomodulatory drugs (IMiDs), and CD38 …

Introduction of fluorine into bioactive molecules has attracted much attention in drug
development. For example, tetrafluorination of the phthalimide moiety of immunomodulatory …

The survival rate of pediatric acute myeloid leukemia (pAML) is currently around 60%. While
survival has slowly increased over the past few decades, the development of novel agents …

Long non-coding RNAs (lncRNAs) are crucial regulatory molecules that participate in
numerous cellular development processes, and they have gathered much interest recently …

Robust genetic characterization of paediatric AML has demonstrated that fusion oncogenes
are highly prevalent drivers of AML leukemogenesis in young children. Identification of …